MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ebiom.2022.104240

Медицинская библиотека · EBioMedicine · 2022

Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.

Ma Ji, Yakass Michael Bright, Jansen Sander, Malengier-Devlies Bert, Van Looveren Dominique, Sanchez-Felipe Lorena, Vercruysse Thomas, Weynand Birgit, Javarappa Mahadesh Prasad Arkalagud, Quaye Osbourne, Matthys Patrick, Roskams Tania, Neyts Johan, Thibaut Hendrik Jan, Dallmeier Kai

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The live-attenuated yellow fever vaccine YF17D holds great promise as alternative viral vector vaccine platform, showcased by our previously presented potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate YF-S0. Besides protection from SARS-CoV-2, YF-S0 also induced strong yellow fever virus (YFV)-specific immunity, suggestive for full dual activity. A vaccine concomitantly protecting from SARS-CoV-2 and YFV would be of great benefit for those living in YFV-endemic areas with limited access to current SARS-CoV-2 vaccines. However, for broader applicability, pre-existing vector immunity should not impact the potency of such YF17D-vectored vaccines.

METHODS

The immunogenicity and efficacy of YF-S0 against YFV and SARS-CoV-2 in the presence of strong pre-existing YFV immunity were evaluated in mouse and hamster challenge models.

FINDINGS: Here, we show that a single dose of YF-S0 is sufficient to induce strong humoral and cellular immunity against YFV as well as SARS-CoV-2 in mice and hamsters; resulting in full protection from vigorous YFV challenge in either model; in mice against lethal intracranial YF17D challenge, and in hamsters against viscerotropic infection and liver disease following challenge with highly pathogenic hamster-adapted YFV-Asibi strain. Importantly, strong pre-existing immunity against the YF17D vector did not interfere with subsequent YF-S0 vaccination in mice or hamsters; nor with protection conferred against SARS-CoV-2 strain B1.1.7 (Alpha variant) infection in hamsters.

INTERPRETATION: Our findings warrant the development of YF-S0 as dual SARS-CoV-2 and YFV vaccine. Contrary to other viral vaccine platforms, use of YF17D does not suffer from pre-existing vector immunity.

FUNDING: Stated in the acknowledgments.

Для цитирования: Ma Ji, Yakass Michael Bright, Jansen Sander, Malengier-Devlies Bert, Van Looveren Dominique, Sanchez-Felipe Lorena, Vercruysse Thomas, Weynand Birgit, Javarappa Mahadesh Prasad Arkalagud, Quaye Osbourne, Matthys Patrick, Roskams Tania, Neyts Johan, Thibaut Hendrik Jan, Dallmeier Kai. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.. EBioMedicine. 2022. DOI: 10.1016/j.ebiom.2022.104240.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.